We came to the consensual conclusion that the LDT-assay developed by our laboratory shows better analytical performance than FISH (also detectable in the current study) and would be useful also in patients with HER2-low breast cancer (sample no. 4), so that more patients could benefit from anti-HER2 treatment. Here, ERBB2 is linked to breast carcinoma.